Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of BI 409306 in schizophrenia
2013-005015-28Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing BI 409306 with Placebo (2 arms). Primary endpoint: Change in cognitive function (CANTAB). Started Aug 2014; status: completed.
02
Drugs
osoresnontrine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2013-005015-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005015-28.